The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Autologous Transplant in Gray Zone Lymphoma
Mohammed Kharfan-Dabaja of the Moffitt Cancer Center in Tampa, Florida, and colleagues investigated outcomes in Gray Zone Lymphoma (GZL) patients after autologous stem cell transplant. The findings were published online December 7, 2017, in the journal Biology of Blood and Marrow Transplantation.
Gray Zone Lymphoma has features which are intermediate between Diffuse Large B-Cell Lymphoma and classical Hodgkin’s Lymphoma. GZL is very rare, and there is no standard treatment recommendation for this diagnosis. The goal of this study was to review therapy outcomes for relapsed or refractory GZL after autologous stem cell transplant (SCT).
Patient Population
- N = 32 patients
- Median age = 38 years
- Prep regimens
- BEAM (carmustine, etoposide, cytarabine, melphalan) = 59%
- BEAM-R (BEAM + rituximab) = 13%
- Other regimens = 28%
- Number of therapies prior to SCT
- One = 25%
- More than one = 75%
- Median stem cell dose = 4.93 x 106 cells/kg
Key Findings
- Median time to neutrophil and platelet engraftment = 11 days
- Response after 1 year
- Complete remission (CR) = 57.1%
- Partial remission (PR) = 28.5%
- Relapse = 9.5%
- Three-year overall survival (OS) = 78% (95% CI, 61%–95%)
- Patients in CR or not in CR had no difference in 3-year OS
- Number of prior therapies made no difference in 3-year OS
- Three-year progression-free survival (PFS) = 69% (95% CI, 49%–88%)
- Patients in CR or not in CR had no difference in 3-year PFS
- Number of prior therapies made no difference in 3-year PFS
- Three-year relapse/progression = 31% (95% CI, 17%–59%)
- Three-year non-relapse mortality (NRM) = 0 patients
These findings suggest that autologous transplant may be a suitable treatment option for Gray Zone Lymphoma. The results of this observation should be validated in a larger, prospective study, to confirm outcomes of autologous transplant in this population.
References